

Academic Appointments

- Professor, Boston University School of Law (2007 – present) (promoted 2013); N. Neal Pike Scholar in Health and Disability Law (2014 – 2022); Arthur B Fletcher Professor of Law (2023-present)
- Director, Social Innovation on Drug Resistance (SIDR) Program, Boston University (2019-present)
- Associate Professor of Health Law, Policy & Management, Boston University School of Public Health (2010 – present)
- Faculty Co-Editor, American Journal of Law & Medicine (2007 – present)
- Editor-In-Chief, Journal of Law, Medicine & Ethics (2010 – 2016)
- Associate Fellow, Centre for Global Health Security, Royal Institute for International Affairs (Chatham House, London) (2014 – present)
- Visiting Professor, University of Iowa College of Law (2013)
- Professor, West Virginia University College of Law (2002 – 2007) (promoted 2006)

Education

- University of Cambridge, England (LL.M., 2002)
- Northwestern University (J.D., 1987); (B.S., 1984) *with distinction*
- University of Reading, England (Rotary Scholar, 1982-83)

Legal Experience

- Shareholder, Baker Donelson, Nashville, TN (1996-2002, transactional health care law)
- Income partner, McDermott, Will & Emery, Chicago, Illinois (1989-1994, federal and international corporate taxation)
- Associate, Lord, Bissell & Brook, Chicago, Illinois (1987-1989, tax associate)
- Expert witness on corporate governance, and food & drug law in federal and state courts, including depositions and trial (bench and jury) (2006-present)

Leadership & Awards

- Founding Executive Director, CARB-X (2016-present) CARB-X is the world's most innovative antibacterial R&D accelerator, supporting 92 projects in 12 countries thus far.
- International Network for Antimicrobial Resistance Social Science (INAMRSS) (Founder & Executive Committee, 2019-present)
- G20 Global AMR R&D Hub (Appointed Stakeholder, 2019-present)
- Leadership Award, Alliance for the Prudent Use of Antibiotics (2015)
- Co-director of the health law program at BU Law (2007 – present)
- Board, American Society of Law, Medicine & Ethics (2010 – 2018), Chair (2017)

- Chair, Section on Law, Medicine & Healthcare, Association of American Law Schools (2010-2011); Executive Committee (2008-2013)
- Boston Faculty Fellowship (2008-2016) (founding leadership team)
- Faculty Senate Executive Committee & University Promotion and Tenure Committee, West Virginia University (2006-2007)
- Managed teams of attorneys and large client engagement budgets; recruiting and mentoring new hires; and new client relationship development; in positions with increasing levels of responsibility, culminating as a full partner in a major law firm (1987-2001)

Funded Research

- Principal Investigator – CARB-X Other Transactions Agreement with US HHS/BARDA \$300,000,000 (2022-2032).
- Principal Investigator – CARB-X Award Letter from the Wellcome Trust, \$70,000,000 (2022-2024).
- Principal Investigator – CARB-X, €39,000,000 grant from the German Federal Ministry for Education and Research (BMBF) (2019-2023).
- Principal Investigator – CARB-X, \$25,000,000 grant from the Bill & Melinda Gates Foundation (2018-2022).
- Principal Investigator – CARB-X, £20,000,000 grant from the UK Department of Health and Social Care (2018-2022).
- Principal Investigator – CARB-X Award Letter from the Wellcome Trust, \$155,500,000 (2017-2021).
- Principal Investigator – CARB-X Cooperative Agreement with US HHS/BARDA (IDSEP160030-01-00) \$250,000,000 (2016-2021).
- Partner, DRIVE-AB €9,200,000 grant from the European Union's Innovative Medicines Initiative to study business models and incentives for antibiotic development (PI: Stephan Harbarth, Geneva) (2014-2017)
- Senior Technical Advisor, US HHS/FDA: *Incentives for the development of new drugs, vaccines, and rapid diagnostics for bacterial diseases*. (PI – Eastern Research Group. Prime Contract No. HHSP23320095634WC), \$50,000 (2011-12)
- PI - RWJF Public Health Law Research: *Studying the public health implications of antibiotic drug regulation*. Contract 67136, \$149,996 (Dec. 2009 – May 2011)
- PI – David Saul Smith Foundation: *Legal incentives & antimicrobial resistance*. \$20,000 (2010-2011)

Courses Taught

- Corporations
- Health Care Law
- US Corporate Law for International Lawyers
- Constitutional Health Care Litigation
- Health Care Transactions
- Food & Drug Law
- Property
- Administrative Rulemaking in Health Care

Other Teaching

- Harvard School of Public Health, Biology & Epidemiology of Antibiotic Resistance (Prof. Marc Lipsitch, 2008, 2010, 2012, 2016, 2018, 2020)
- Harvard College (Prof. Dan Wikler, 2010)
- Harvard Law School (Prof. William Fisher, 2010)
- MIT Vaccine Development class (Prof. Chris Love, 2009-2011)
- Northeastern Univ. School of Law (Corporations, fall semester 2010)

Service

- Research and policy work on incentives for antibiotic development and conservation with Brookings, the CDC, FDA, Robert Wood Johnson Foundation, the Royal Institute for International Affairs (Chatham House), Dag Hammarskjöld Foundation, Duke-Margolis Center, and other groups (2009-present).
- Member of the Governor's Special Commission on Pharmacy Compounding (2012), created in response to the NECC compounding pharmacy disaster.
- Peer Reviewer for: New England Journal of Medicine; Health Affairs; PLoS Medicine; American Journal of Law & Medicine; Journal of Law, Medicine & Ethics; Global Public Health; Australian Health Review; Jurimetrics; Bioethics; Social Science & Medicine; Health Policy & Planning; Ethics & International Affairs; Journal of World Intellectual Property; Journal of Pharmaceutical Sciences; Journal of Women, Politics & Policy; Journal of the International AIDS Society; Stanford Journal of Law, Science & Policy; Government of Qatar; Journal of the American Informatics Association; BMJ Global Health; Yale Journal of Health Policy, Law & Ethics.
- Keynote speaker at donor development events for Boston University's \$1.8B capital campaign in Houston, Boston, Washington, D.C, Seattle, Los Angeles, and San Francisco (2011-present).
- *Pro bono* consultant to governments and legislatures on health policy issues (Massachusetts, Vermont, California, West Virginia, US Congress).
- BU Law committees: JD (Chair); Lateral Appointments (2019-2020).

Publications and Professional Papers¹

Peer reviewed papers, law journals articles, books, book chapters & monographs:

100. Madden J, Outterson K. Trends in the global antibiotics market. *Nat Rev Drug Disc.* 2023 Mar; 22(3):174.

99. Huberfeld N, Weeks E, Outterson K, Lawrence M (2023). *The Law of American Health Care* (Third Edition). Aspen Pub.

98. Outterson K. Estimating the appropriate size of a global antibacterial pull incentive. *Health Affairs.* 2021; 40(11):1758-1765.

¹ [Google scholar](#) h-index = 35, i10-index = 61.

97. Amila K. Nanayakkara, PhD; Helen W. Boucher, MD; Vance G. Fowler, Jr, MD, MHS; Amanda Jezek; Kevin Outterson, JD, LLM; David E. Greenberg, MD, Antibiotic Resistance in the Patient With Cancer: Escalating Challenges and Paths Forward. *CA Cancer J. Clin.* 2021;71(6):488-504.
96. Colson AR, Morton A, Årdal C, Chalkidou K, Davies SC, Garrison LP, Jit M, Laxminarayan R, Megiddo I, Morel CM, Nonvignon J, Outterson K, Rex JH, Sarker AR, Sculpher M, Woods B, Xiao Y. Antimicrobial resistance: is health technology assessment part of the solution or part of the problem? *Value in Health.* 2021;24(12):1828-1834.
95. Outterson K, Orubu ESF, Rex J, Årdal C, Zaman MH. Patient access in fourteen high-income countries to new antibacterials approved by the FDA, EMA, PMDA, or Health Canada, 2010-2020. *Clin Inf Dis.* 2021 Jul 12;ciab612. doi: 10.1093/cid/ciab612. Online ahead of print.
94. Kållberg C, Hudson J, Blix HS, Årdal C, Klein E, Lindbæk, Outterson K, et al. The effect of generic market entry on antibiotic prescriptions in the United States. *Nat Comms.* 2021;12(1):1-9.
93. Boucher HW, File TM, Fowler VG, Jezek A, Rex JH, Outterson K. Antibiotic development incentives that reflect societal value of antibiotics. *Clin Inf Dis.* 2021;72(9):e420-e421.
92. Puzniak L, Gupta V, Kalvin CY, Ye G, Outterson K. The impact of infections on reimbursement in 92 US hospitals, 2015-2018. *Am J Inf Control* 2021.
91. Kim W, Krause K, Zimmerman Z, Outterson K. Improving data sharing to increase the efficiency of antibiotic R&D. *Nat Reviews Drug Discovery* 2021;20:1-2 doi: <https://doi.org/10.1038/d41573-020-00185-4>.
90. Minssen T, Outterson K, Van Katwyk SR, Batista PHD, Chandler CIR, et al. Social, cultural and economic aspects of antimicrobial resistance. *Bull WHO* 98(12):823 (2020).
89. Kirchhelle C, Atkinson P, Broom A, Chuengsatiansup K, Ferreira JP, Fortané N, Frost I, Gradmann C, Hinchliffe S, Hoffman SJ, Lezaun J, Nayiga S, Outterson K, Podolsky SH, Raymond S, Roberts AP, Singer AC, So AD, Sringernyung L, Tayler E, Van Katwyk SR, Chandler CIR. Setting the standard: multidisciplinary hallmarks for structural, equitable and tracked antibiotic policy. *BMJ Global Health* 2020 e003091.
88. Rex JH, Outterson K. Antibacterial R&D at a crossroads: We've pushed as hard as we can ... now we need to start pulling! [published online ahead of print, 2020 Jun 25]. *Clin Infect Dis.* 2020 doi:10.1093/cid/ciaa852.
87. Morel C, Alm R, Ardal C, Bandera A, Bruno G, et al. A One Health framework to estimate costs of antimicrobial resistance. (pre-print, 2020).
86. Laxminarayan R, Van Boeckel T, Frost I, Kariuki S, Khan EA, Limmathurotsakul D, Larsson DGJ, Levy-Hara G, Mendelson M, Outterson K, Peacock SJ, Zhu, Y-G (2020). The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later. *Lancet Infect Dis*, 20(4), e51-e60. doi:[10.1016/S1473-3099\(20\)30003-7](https://doi.org/10.1016/S1473-3099(20)30003-7).
85. Outterson K, & Rex J H (2020). Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization. *Transl Res.* 2020 Jun;220:182-190. doi:[10.1016/j.trsl.2020.02.006](https://doi.org/10.1016/j.trsl.2020.02.006).
84. Boucher HW, File TM, Fowler VG, Jezek A, Rex JH, Outterson K. Antibiotic development incentives that reflect societal value of antibiotics. *Clin Infect Dis.* 2020;ciaa092. doi:10.1093/cid/ciaa092.

83. Theuretzbacher U, Outterson K, Engel A, Karlen A (2019). The global preclinical antibacterial pipeline. *Nat Rev Microbiology* (epub 19 Nov. 2019).
82. Ardal C, Balasegaram M, Laxminarayan R, McAdams D, Outterson K, Rex JH, Sumpradit N (2020). Antibiotic development – economic, regulatory and societal challenges. *Nat Rev Microbiology* (epub 19 Nov. 2019).
81. Van Katwyk SR, Balasegaram M, Boriello SP, Farrar J, Giubilini A, Harrison M, Kieny M-P, Kirchhelle C, Liu J, Outterson K, Pate MA, Poirier M, Røttingen J-A, Savulescu J, Sugden R, Thamlikitkul V, Weldon I, Davies S, Hoffman SJ (2019). A roadmap for sustainably governing the global antimicrobial commons. *Lancet*, 394(10211):1788.
80. Outterson K (2019). A shot in the arm for new antibiotics. *Nat Biotechnology*, 37(10):1110-1112.
79. Rex JH, Fernandez Lynch H, Cohen IG, Darrow JJ, & Outterson K (2019). Designing development programs for non-traditional antibacterial agents. *Nat Commun*, 10(1), 1-10.
78. Huberfeld N, Weeks E, Outterson K (2018). *The Law of American Health Care* (Second Edition). Aspen Pub.
77. Årdal C, Baraldi E, Theuretzbacher U, Outterson K, Plahte J, Ciabusch F, & Røttingen JA (2018). Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations. *J Pharm Policy Pract*, 11(1), 8.
76. Kallberg C, Ardal C, Blix HS, Klein E, Martinez EM, Lindbaek M, Outterson K, Røttingen JA, Laxminarayan R (2018). Introduction and geographic availability of new antibiotics approved between 1999 and 2014. *PLOS ONE*, 13(10), e0205166. doi:[10.1371/journal.pone.0205166](https://doi.org/10.1371/journal.pone.0205166)
75. Bhatti T, Lum K, Holland S, Sassman S, Findlay D, & Outterson K (2018). A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All. *JOURNAL OF LAW, MED & ETHICS*, 46(1), 59-65. doi:[10.1177/1073110518782916](https://doi.org/10.1177/1073110518782916)
74. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL, Pulcini C, Kahlmeter G, Kluytmans J, Carmeli Y, Ouellette M, Outterson K, Patel J, Cavalieri M, Cox E, Houchens C, Grayson ML, Hansen P, Zorzet A, et al (2018). Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. *LANCET INFECTIOUS DISEASES*, 18(3), 318-327. doi:[10.1016/S1473-3099\(17\)30753-3](https://doi.org/10.1016/S1473-3099(17)30753-3)
73. Ardal CO, Findlay D, Savic M, Carmeli Y, Gyssens I, Laxminarayan R, Outterson K, Rex JH (2018). Revitalizing the antibiotic pipeline: Stimulating innovation while driving sustainable use and global access. DRIVE-AB Final Report (European Commission, Innovative Medicines Initiative).
72. Theuretzbacher U, Savic M, Ardal C, & Outterson K (2017). Innovation in the preclinical antibiotic pipeline. *NATURE REVIEWS DRUG DISCOVERY*, 16(11), 744-745. doi:[10.1038/nrd.2017.195](https://doi.org/10.1038/nrd.2017.195)
71. Barlam TF, Morgan JR, Kaplan WA, Outterson K, & Pelton SI (2017). Disproportionate Exposure to Antibiotics in Children at Risk for Invasive Pneumococcal Disease: Potential for Emerging Resistance and Opportunity for Antibiotic Stewardship. *J Pediatric Infect Dis Soc*, 8(1), 63-65. doi:[10.1093/jpids/pix070](https://doi.org/10.1093/jpids/pix070)
70. Ardal C, Baraldi E, Ciabusch F, Outterson K, Rex JH, Piddock LJV, & Findlay D (2017). To the G20: incentivising antibacterial research and development. *LANCET INFECTIOUS DISEASES*, 17(8), 799-801. doi:[10.1016/S1473-3099\(17\)30404-8](https://doi.org/10.1016/S1473-3099(17)30404-8)
69. Deak D, Powers JH, Outterson K, & Kesselheim AS (2017). The Fight Against Multidrug-Resistant Bacteria. Response. *ANNALS OF INTERNAL MEDICINE*, 166(1), 79. doi:[10.7326/L16-0582](https://doi.org/10.7326/L16-0582)

68. Outterson K, Huberfeld N, & Weeks E (2017). Teaching the Law of American Health Care. *Saint Louis University Law Journal*, 61(3), 401-410.
67. Huberfeld N, Weeks E, Outterson K (2016). The Law of American Health Care. Aspen Pub.
66. Outterson K, & McDonnell A (2016). Antimicrobial Resistance: The Authors Reply. *HEALTH AFFAIRS*, 35(10), 1936. doi:[10.1377/hlthaff.2016.1106](https://doi.org/10.1377/hlthaff.2016.1106)
65. Deak D, Outterson K, Powers JH, & Kesselheim AS (2016). Progress in the Fight Against Multidrug-Resistant Bacteria? A Review of US Food and Drug Administration-Approved Antibiotics, 2010-2015. *ANNALS OF INTERNAL MEDICINE*, 165(5), 363-+. doi:[10.7326/M16-0291](https://doi.org/10.7326/M16-0291)
64. Outterson , Rex, JH, Jinks T, Jackson P, Hallinan J, Karp S, Larsen J, et al (2016). Accelerating global innovation to address antibacterial resistance: introducing CARB-X. *NATURE REVIEWS DRUG DISCOVERY*, 15(9), 589-590. doi:[10.1038/nrd.2016.155](https://doi.org/10.1038/nrd.2016.155)
63. Outterson K, Gopinathan U, Clift C, So AD, Morel CM, & Rottingen JA (2016). Delinking Investment in Antibiotic Research and Development from Sales Revenues: The Challenges of Transforming a Promising Idea into Reality. *PLOS MEDICINE*, 13(6), 7 pages. doi:[10.1371/journal.pmed.1002043](https://doi.org/10.1371/journal.pmed.1002043)
62. Outterson K, & McDonnell A (2016). Funding Antibiotic Innovation With Vouchers: Recommendations On How To Strengthen A Flawed Incentive Policy. *HEALTH AFFAIRS*, 35(5), 784-790. doi:[10.1377/hlthaff.2015.1139](https://doi.org/10.1377/hlthaff.2015.1139)
61. Rex JH, & Outterson K (2016). Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach. *LANCET INFECTIOUS DISEASES*, 16(4), 500-505. doi:[10.1016/S1473-3099\(15\)00500-9](https://doi.org/10.1016/S1473-3099(15)00500-9)
60. Ardal C, Outterson K, Hoffman SJ, Ghafur A, Sharland M, Ranganathan N, Rottingen JA, et al (2016). International cooperation to improve access to and sustain effectiveness of antimicrobials. *LANCET*, 387(10015), 296-307. doi:[10.1016/S0140-6736\(15\)00470-5](https://doi.org/10.1016/S0140-6736(15)00470-5)
59. Clift C, Gopinathan U, Morel C, Outterson K, Rottingen JA, So A (2015). Towards a New Global Business Model for Antibiotics: Report from the Chatham House Working Group on New Antibiotic Business Models. London.
58. Harbarth, S., Theuretzbacher, U., Hackett, J., Adriaenssens, N., Anderson, J., Antonisse, A., . . . Zorzet, A. (2015). Antibiotic research and development: business as usual? *JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY*, 70(6), 1604-1607. doi:[10.1093/jac/dkv020](https://doi.org/10.1093/jac/dkv020)
57. Hoffman, S. J., & Outterson, K. (2015). What Will It Take to Address the Global Threat of Antibiotic Resistance?. *JOURNAL OF LAW MEDICINE & ETHICS*, 43(2), 363-368. doi:[10.1111/jlme.12253](https://doi.org/10.1111/jlme.12253)
56. Jaczynska E, Outterson K, Menstre-Ferrandiz J (2015). Business model options for antibiotics: Learning from other industries. Chatham House, London.
55. Outterson, K., Powers, J. H., Daniel, G. W., & McClellan, M. B. (2015). Repairing the broken market for antibiotic innovation. *HEALTH AFFAIRS*, 34(2), 277-285. doi:[10.1377/hlthaff.2014.1003](https://doi.org/10.1377/hlthaff.2014.1003)
54. Hoffman SJ, Outterson K, Rottinge JA, Cars O, Clift C, Rizvi Z, . . . Zorzet A (2015). An international legal framework to address antimicrobial resistance. *BULLETIN OF THE WORLD HEALTH ORGANIZATION*, 93(2), 66. doi:[10.2471/BLT.15.152710](https://doi.org/10.2471/BLT.15.152710)
53. Sertkaya A, Eyraud J, Birkenbach A, Franz C, Ackerley N, Overton V, Outterson K (2014). Analytical Framework for Examining the Value of Antibacterial Products (For US Department of Health & Human Services/ASPE, April 15, 2014) http://aspe.hhs.gov/sp/reports/2014/antibacterials/rpt_antibacterials.cfm.

52. Outterson K (2014). New Business Models for Sustainable Antibiotics, Chatham House Centre on Global Health Security Working Group Papers (London).
51. Outterson K (2014). AHLA Health Law Curriculum Manual. American Health Lawyers Association.
50. Outterson, K. (2014). The Drug Quality and Security Act - Mind the Gaps. *NEW ENGLAND JOURNAL OF MEDICINE*, 370(2), 97-99. doi:[10.1056/NEJMp1314691](https://doi.org/10.1056/NEJMp1314691)
49. Outterson, K. (2014). Clinical Trial Transparency - Antidote to Weaker Off-Label-Promotion Rules?. *NEW ENGLAND JOURNAL OF MEDICINE*, 371(1), 1-3. doi:[10.1056/NEJMp1402969](https://doi.org/10.1056/NEJMp1402969)
48. Huberfeld, N., Leonard, E. W., & Outterson, K. (2013). Plunging into endless difficulties: Medicaid and coercion in National Federation of Independent Business v. Sebelius. *BOSTON UNIVERSITY LAW REVIEW*, 93(1), 1-88.
47. Outterson, K., Powers, J. H., Seoane-Vazquez, E., Rodriguez-Monguiro, R., & Kesselheim, A. S. (2013). Approval and Withdrawal of New Antibiotics and Other Antiinfectives in the U.S., 1980-2009. *JOURNAL OF LAW MEDICINE & ETHICS*, 41(3), 688-696. doi:[10.1111/jlme.12079](https://doi.org/10.1111/jlme.12079)
46. Pogge T, Hollis A, Outterson K (2013). Combatting Antibiotic Resistance Through the Health Impact Fund in THE GLOBALIZATION OF HEALTH CARE: LEGAL AND ETHICAL ISSUES (Glenn I. Cohen, ed., Oxford University Press, 2013).
45. Outterson, K. (2012). All Pain, No GAIN: Need for Prudent Antimicrobial Use Provisions to Complement the GAIN Act. *APUA Clinical Newsletter*, 30(1), 13.
44. Speiser, S., & Outterson, K. (2012). Deductions for Drug Ads? The Constitution Does Not Require Congress to Subsidize Direct-to-Consumer Prescription Drug Advertisements. *Santa Clara Law Review*, 52, 453.
43. Outterson, K. (2012). Regulating Compounding Pharmacies after NECC. *NEW ENGLAND JOURNAL OF MEDICINE*, 367(21), 1969-1972. doi:[10.1056/NEJMp1212667](https://doi.org/10.1056/NEJMp1212667)
42. Outterson, K. (2012). Punishing Health Care Fraud - Is the GSK Settlement Sufficient?. *NEW ENGLAND JOURNAL OF MEDICINE*, 367(12), 1082-1085. doi:[10.1056/NEJMp1209249](https://doi.org/10.1056/NEJMp1209249)
41. Eisenberg, C. B., & Outterson, K. (2012). Agents Without Principals: Regulating the Duty of Loyalty for Nonprofit Corporations Through the Intermediate Sanctions Tax Regulations. *Journal of Business, Entrepreneurship and the Law*, 5(2).
40. Outterson K, Yevtukhova O (2011). Germ Shed Management in the United States, in ANTIBIOTIC POLICIES: CONTROLLING HOSPITAL-ASSOCIATED INFECTION (Ian M. Gould and Jos van der Meer, eds., Springer, 2011).
39. So, A. D., Gupta, N., Brahmachari, S. K., Chopra, I., Munos, B., Nathan, C., . . . Weigelt, J. (2011). Towards new business models for R&D for novel antibiotics. *DRUG RESISTANCE UPDATES*, 14(2), 88-94. doi:[10.1016/j.drug.2011.01.006](https://doi.org/10.1016/j.drug.2011.01.006)
38. Outterson, K. (2011). Smoking and the First Amendment. *NEW ENGLAND JOURNAL OF MEDICINE*, 365(25), 2351-2353. doi:[10.1056/NEJMp1113011](https://doi.org/10.1056/NEJMp1113011)
37. Outterson, K., Selinger, E., & Whyte, K. (2011). Poverty Tourism, Justice, and Policy. *Public Integrity*, 14(1), 39-50. doi:[10.2753/pin1099-9922140103](https://doi.org/10.2753/pin1099-9922140103)
36. Whyte, K. P., Selinger, E., & Outterson, K. (2011). Poverty tourism and the problem of consent. *Journal of Global Ethics*, 7(3), 337-348. doi:[10.1080/17449626.2011.635689](https://doi.org/10.1080/17449626.2011.635689)

35. Outterson, K. (2011). Higher First Amendment Hurdles for Public Health Regulation. *NEW ENGLAND JOURNAL OF MEDICINE*, 365(7), 3 pages.
34. Kesselheim, A. S., & Outterson, K. (2011). Improving antibiotic markets for long-term sustainability. *Yale J Health Policy Law Ethics*, 11(1), 101-167.
33. Outterson, K. (2010). The Legal Ecology of Resistance: The Role of Antibiotic Resistance in Pharmaceutical Innovation. *Cardozo Law Review*, 31, 613.
32. Selinger, E., & Outterson, K. (2010). The Ethics of Poverty Tourism. *Environmental Philosophy*, 7(2), 93-114. doi:[10.5840/enviophil20107217](https://doi.org/10.5840/enviophil20107217)
31. Outterson, K., Powers, J. H., Gould, I. M., & Kesselheim, A. S. (2010). Questions about the 10 x '20 Initiative. *CLINICAL INFECTIOUS DISEASES*, 51(6), 751-752. doi:[10.1086/655955](https://doi.org/10.1086/655955)
30. Kesselheim, A. S., & Outterson, K. (2010). Fighting Antibiotic Resistance: Marrying New Financial Incentives To Meeting Public Health Goals. *HEALTH AFFAIRS*, 29(9), 1689-1696. doi:[10.1377/hlthaff.2009.0439](https://doi.org/10.1377/hlthaff.2009.0439)
29. Outterson K (2010). Disease-Based Limitations On Compulsory Licenses Under Articles 31 and 31 bis, in *RESEARCH HANDBOOK ON INTELLECTUAL PROPERTY LAW AND THE WTO* (Carlos Correa, ed., Edward Elgar, 2010).
28. Outterson, K. (2010). Death from the Public Domain?. *Texas Law Review* (<i>See Also</i> Online Supplement), 87, 45-55.
27. Outterson K (2009). Import Safety Rules And Generic Drug Markets, in *IMPORT SAFETY: REGULATORY GOVERNANCE IN THE GLOBAL ECONOMY* (Cary Coglianese, Adam Finkel, & David Zaring, eds., 2009) (The University of Pennsylvania Press).
26. Outterson K, Light DW (2009). Global Pharmaceutical Markets, in *A COMPANION TO BIOETHICS* (2ND ED.) (BLACKWELL COMPANIONS TO PHILOSOPHY) (Helga Kuhse & Peter Singer, eds.) (Blackwell, 2009).
25. Outterson, K. (2009). Introduction: Pharmaceutical Innovation: Law & the Public's Health. *JOURNAL OF LAW MEDICINE & ETHICS*, 37(2), 173-175. doi:[10.1111/j.1748-720X.2009.00363.x](https://doi.org/10.1111/j.1748-720X.2009.00363.x)
24. Outterson, K. (2009). The End of Reparations Talk? - Reparations in an Obama World. *Kansas Law Review*, 57(4).
23. Outterson, K., & Kesselheim, A. S. (2009). How Medicare Could Get Better Prices On Prescription Drugs. *HEALTH AFFAIRS*, 28(5), W832-W841. doi:[10.1377/hlthaff.28.5.w832](https://doi.org/10.1377/hlthaff.28.5.w832)
22. Outterson, K. (2009). Foreword - Will HPV Vaccines Prevent Cervical Cancers Among Poor Women of Color?: Global Health Policy at the Intersection of Human Rights and Intellectual Property Law. *AMERICAN JOURNAL OF LAW & MEDICINE*, 35(2-3), 247-252. doi:[10.1177/009885880903500201](https://doi.org/10.1177/009885880903500201)
21. Outterson, K. (2008). Should access to medicines and TRIPS flexibilities be limited to specific diseases?. *AMERICAN JOURNAL OF LAW & MEDICINE*, 34(2-3), 279-301. doi:[10.1177/009885880803400208](https://doi.org/10.1177/009885880803400208)
20. Outterson, K., & Kesselheim, A. S. (2008). Market-based licensing for HPV vaccines in developing countries. *HEALTH AFFAIRS*, 27(1), 130-139. doi:[10.1377/hlthaff.27.1.130](https://doi.org/10.1377/hlthaff.27.1.130)
19. Outterson, K. (2008). Antibiotic resistance and antibiotic development - Author's reply. *LANCET INFECTIOUS DISEASES*, 8(4), 212-214. doi:[10.1016/S1473-3099\(08\)70049-5](https://doi.org/10.1016/S1473-3099(08)70049-5)

18. Outterson, K., Samora, J. B., & Keller-Cuda, K. (2007). Will longer antimicrobial patents improve global public health?. *LANCET INFECTIOUS DISEASES*, 7(8), 559-566. doi:[10.1016/S1473-3099\(07\)70188-3](https://doi.org/10.1016/S1473-3099(07)70188-3)
17. Outterson K (2007). *International Pharmaceutical Issues*, in THE FUNDAMENTALS OF LIFE SCIENCES LAW: DRUGS, DEVICES, AND BIOTECH (American Health Lawyers Association, 2007).
16. Outterson K (2006). Fair Followers: Expanding Access To Generic Pharmaceuticals For Low- and Medium-Income Populations, in THE POWER OF PILLS: SOCIAL, ETHICAL AND LEGAL ISSUES IN DRUG DEVELOPMENT, MARKETING AND PRICING (Jillian Clare Cohen, Patricia Illingworth, and Udo Schuklenk, eds.) (London: Pluto Press, 2006). Translated into Portuguese: 'Fair Followers': Expandindo o Acesso a Medicamentos Genéricos para a População de Baixa e Média Renda, in PROPRIEDADE INTELECTUAL: NOVOS PARADIGMAS INTERNACIONAIS, CONFLITOS E DESAFIOS (Campus-Elsevier, Brasil 2007).
15. Outterson, K. (2006). Patent buy-outs for global disease innovations for low- and middle-income countries. *AMERICAN JOURNAL OF LAW & MEDICINE*, 32(2-3), 159-173. doi:[10.1177/009885880603200202](https://doi.org/10.1177/009885880603200202)
14. Outterson, K., & Smith, R. (2006). Counterfeit Drugs: The Good, the Bad and the Ugly. *Albany Law Journal of Science and Technology*, 15.
13. Outterson, K. (2005). Tragedy and remedy: reparations for disparities in black health. *DePaul J Health Care Law*, 9(1), 735-791. Retrieved from <https://www.ncbi.nlm.nih.gov/pubmed/17061385>
12. Outterson, K. (2005). The vanishing public domain: Antibiotic resistance, pharmaceutical innovation and intellectual property law. *UNIVERSITY OF PITTSBURGH LAW REVIEW*, 67(1), 67-123.
11. Outterson, K. (2005). Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets. *Yale J Health Policy Law Ethics*, 5(1), 193-291.
10. Outterson, K. (2005). Agony in the Antipodes: The generic drug provisions of the Australia-USA Free Trade Agreement. *Journal of Generic Medicines*, 2(4), 316-326. doi:[10.1057/palgrave.jgm.4940084](https://doi.org/10.1057/palgrave.jgm.4940084)
9. Outterson K (2004). Slave Taxes, in SHOULD AMERICA PAY?: SLAVERY AND THE RAGING DEBATE OVER REPARATIONS (Raymond Winbush, ed.) (New York: Harper Collins 2003), *reprinted in* STUDIES IN THE HISTORY OF TAX LAW (John Tiley, ed.) (Oxford: Hart Publishing 2004).
8. Outterson, M. K. (2004). Free trade in pharmaceuticals. *MEDICAL JOURNAL OF AUSTRALIA*, 181(5), 260-+.
7. Outterson, K. (2004). Free Trade Against Free Riders? *Pharma Pricing & Reimbursement*, 9(9), 254-255.
6. Outterson, M. K. (2001). GP corporatisation: lessons to be learned. *MEDICAL JOURNAL OF AUSTRALIA*, 175(8), 426-427.
5. Outterson K, Miley C, Butler J (1999). DISEASE MANAGEMENT AND GAINSHARING: THE NEXT GENERATION OF MANAGED CARE, AHLA Monograph, 2nd ed., 1999).
4. Outterson, K., & Butler, J. L. (1998). Disease management: legal strategies for the next generation of managed care. *J Health Law*, 31(3), 291-314.
3. Kaplan, G., Gilbert, L. P., Faigen, L. E., & Outterson, M. K. (1990). Taxation of insurance companies – recent developments. *TORT & INSURANCE LAW JOURNAL*, 25(2), 458-475.

2. Outterson, K., Cheung C. Revenue Procedure 91-12: The IRS Launches An Information-Gathering Offensive Against International Transportation Operations, 91 TAX NOTES INTERNATIONAL 71 (1991).

1. Outterson, K. Taxation Without Premeditation: An Economic Analysis of The Structure, Regulation and Strangulation of the Private Activity Bond Market, 6 BOSTON UNIV. J. OF TAX L. 1-36 (1988).

Government testimony & legal briefs (*pro bono publico*), newspaper op/eds & other:

25. Outterson K (2019). Comment letter on Medicare Program; Hospital Inpatient Prospective Payment System for Acute Care Hospitals FY2020 [CMS-1716-P].

24. Outterson K (2018). Innovative ways to pay for new antibiotics will help fight superbugs. *STAT* (April 11, 2018), <https://www.statnews.com/2018/04/11/innovation-new-antibiotics-fight-superbugs/>.

23. Bagley N, Outterson K (2017). We will miss antibiotics when they're gone. *NY Times*, Jan. 18, 2017 (OpEd).

22. *Testimony before the Massachusetts Joint Committee on Health Care Financing* (on drug price transparency), April 11, 2016.

21. *Testimony before the United Nations High-Level Panel on Access to Medicines*, Feb. 28, 2016 (Antibiotic Delinkage; London, England).

20. *Testimony before the House Energy & Commerce Committee*, Sept. 19, 2014 (on antibiotic resistance) (available here: <http://democrats.energycommerce.house.gov/sites/default/files/documents/Testimony-Outterson-HE-Antibiotic-Resistance-Drug-Development-2014-9-19.pdf>).

19. *Amici Curiae* Brief on Behalf of the Department of Health and Human Services, Florida v. DHHS (the ACA litigation, Medicaid expansion; US Supreme Court, filing Feb. 17, 2012).

18. *Amici Curiae* Brief on Behalf of the Department of Health and Human Services, DHHS v. Florida (the ACA litigation, minimum coverage provision; US Supreme Court, filed Jan. 13, 2012).

17. *Amici Curiae* Brief on Behalf of the New England Journal of Medicine, the Massachusetts Medical Society, the National Physicians Alliance, and the American Medical Students Association in *Sorrell v. IMS Health Inc.* (US Supreme Court, filed March 1, 2011).

16. *Amici Curiae* Brief on Behalf of the New England Journal of Medicine, the Vermont Medical Society, the Massachusetts Medical Society, the New Hampshire Medical Society, the National Physicians Alliance, and the American Medical Students Association, in *IMS v. Sorrell* (2nd Cir. 2009).

15. *Submission on Priority Watch List Treatment for Thailand and Brazil Under Section 182 of the Trade Act of 1974*. Submission to the United States Trade Representative, docket number USTR-2009-0001 (Feb. 17, 2009).

14. *Comments on the Physician Payment Sunshine Act of 2009*. Submission to the U.S. SENATE COMMITTEE ON AGING (Jan. 26, 2009).

13. *Testimony on Pharmaceutical and Medical Device Regulation: Proposed Regulation 105 CMR 970.000*, Submission to the MASSACHUSETTS PUBLIC HEALTH COUNCIL (Jan. 19, 2009).

12. *A Request for Clarification Concerning the Proper Scope of the IGWG's Work to Improve Access to Patented Medicines*, Submission to the WHO IGWG (30 September 2007).

11. *LD 838: An Act Protecting the Confidentiality of Prescription Information*, SUBMISSION TO THE JOINT STANDING COMMITTEE ON HEALTH & HUMAN SERVICES, STATE OF MAINE, (March 28, 2007).

10. *Access to Global Disease Innovation*, SUBMISSION TO WHO INTER GOVERNMENTAL WORKING GROUP (15 Nov. 2006).

9. *Advertising and Marketing of Prescription Drugs*, REPORT OF THE WEST VIRGINIA PHARMACEUTICAL COST MANAGEMENT COUNCIL (Sept. 8, 2005). (Available at <http://www.wvc.state.wv.us/got/pharmacycouncil/sec/default.cfm>).

8. *Response to Thomas C. Arthur's Testimony Before the Committee on Health, Education, Labor, & Pensions, United States Senate*, HEARING ON DRUG IMPORTATION: WOULD THE PRICE BE RIGHT? (April 19, 2005).

7. *States May Reduce Drug Prices With An Eminent Domain Process for Pharmaceutical Patents*, PRESENTATION TO THE HEALTH COMMITTEE OF THE DISTRICT OF COLUMBIA (March 22, 2005).

6. *Testimony Before the Committee on Health, Education, Labor, & Pensions, United States Senate*, HEARING ON: DRUG IMPORTATION: WOULD THE PRICE BE RIGHT? (Feb. 17. 2005).

5. *Nonrival Access To Pharmaceutical Knowledge*, WHO COMMISSION ON INTELLECTUAL PROPERTY RIGHTS, INNOVATION AND PUBLIC HEALTH (Jan. 3, 2005).

4. *Report of the West Virginia Pharmaceutical Cost Management Council* (Sept. 15, 2004). (Available at <http://www.wvc.state.wv.us/got/pharmacycouncil/sec/default.cfm>).

3. *The US-Australia Free Trade Agreement's Unfortunate Attack on Good Healthcare Policy* (testimony submitted to the House Ways & Means Committee, June 22, 2004, in connection with the US-Australia free trade agreement).

2. Expert witness report on corporate governance in *FDIC v. Keystone National Bank, N.A.*, (before US District Court Judge Faber) the largest bank failure in West Virginia's history, and the fourth largest loss to date by the FDIC. (Report, April 28, 2003; testimony at bench trial June 4, 2004).

1. *Amicus Brief on Behalf of Respondents in Gratz v. Bollinger and Grutter v. Bollinger* (the Michigan affirmative action cases) on behalf of the National Coalition of Blacks for Reparations in America and the National Conference of Black Lawyers (filed with the U.S. Supreme Court Feb. 14, 2003).